Home > Research > Publications & Outputs > Paclitaxel (Taxol®) — a guide to administration...

Research

Links

Text available via DOI:

View graph of relations

Paclitaxel (Taxol®) — a guide to administration (Nursing Implications of introducing a new chemotherapeutic agent)

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Published

Standard

Paclitaxel (Taxol®) — a guide to administration (Nursing Implications of introducing a new chemotherapeutic agent). / Preston, Nancy.
In: European Journal of Cancer Care, Vol. 5, No. 3, 1996, p. 147-152.

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Harvard

Preston, N 1996, 'Paclitaxel (Taxol®) — a guide to administration (Nursing Implications of introducing a new chemotherapeutic agent)', European Journal of Cancer Care, vol. 5, no. 3, pp. 147-152. https://doi.org/10.1111/j.1365-2354.1996.tb00226.x

APA

Preston, N. (1996). Paclitaxel (Taxol®) — a guide to administration (Nursing Implications of introducing a new chemotherapeutic agent). European Journal of Cancer Care, 5(3), 147-152. https://doi.org/10.1111/j.1365-2354.1996.tb00226.x

Vancouver

Preston N. Paclitaxel (Taxol®) — a guide to administration (Nursing Implications of introducing a new chemotherapeutic agent). European Journal of Cancer Care. 1996;5(3):147-152. doi: 10.1111/j.1365-2354.1996.tb00226.x

Author

Preston, Nancy. / Paclitaxel (Taxol®) — a guide to administration (Nursing Implications of introducing a new chemotherapeutic agent). In: European Journal of Cancer Care. 1996 ; Vol. 5, No. 3. pp. 147-152.

Bibtex

@article{3746215a2e204f23aad5d77e6cb1f9b7,
title = "Paclitaxel (Taxol{\textregistered}) — a guide to administration (Nursing Implications of introducing a new chemotherapeutic agent)",
abstract = "The introduction of a new chemotherapeutic agent has implications for nursing care. Paclitaxel (Taxol{\textregistered}) chemotherapy is now being used throughout Europe for treatment of patients with ovarian cancer who have previously failed a platinum-containing chemotherapy regimen, and in many countries to treat metastatic breast cancer. Nurses need to be equipped to care for these patients receiving Paclitaxel. This paper introduces nurses to Paclitaxel, the history of its development, its mechanism of action, potential side-effects and administration. Paclitaxel's side-effects include hypersensitivity reactions, neutropaenia, peripheral neuropathy, asymptomatic bradycardia, alopecia, malaise, myalgias and arthralgias. Administration guidelines will be discussed because Paclitaxel leaches plasticizer from polyvinyl chloride (PVC) intravenous-giving sets normally used to administer chemotherapy, hence an alternative delivery system is required.",
author = "Nancy Preston",
year = "1996",
doi = "10.1111/j.1365-2354.1996.tb00226.x",
language = "English",
volume = "5",
pages = "147--152",
journal = "European Journal of Cancer Care",
issn = "1365-2354",
publisher = "Wiley-Blackwell",
number = "3",

}

RIS

TY - JOUR

T1 - Paclitaxel (Taxol®) — a guide to administration (Nursing Implications of introducing a new chemotherapeutic agent)

AU - Preston, Nancy

PY - 1996

Y1 - 1996

N2 - The introduction of a new chemotherapeutic agent has implications for nursing care. Paclitaxel (Taxol®) chemotherapy is now being used throughout Europe for treatment of patients with ovarian cancer who have previously failed a platinum-containing chemotherapy regimen, and in many countries to treat metastatic breast cancer. Nurses need to be equipped to care for these patients receiving Paclitaxel. This paper introduces nurses to Paclitaxel, the history of its development, its mechanism of action, potential side-effects and administration. Paclitaxel's side-effects include hypersensitivity reactions, neutropaenia, peripheral neuropathy, asymptomatic bradycardia, alopecia, malaise, myalgias and arthralgias. Administration guidelines will be discussed because Paclitaxel leaches plasticizer from polyvinyl chloride (PVC) intravenous-giving sets normally used to administer chemotherapy, hence an alternative delivery system is required.

AB - The introduction of a new chemotherapeutic agent has implications for nursing care. Paclitaxel (Taxol®) chemotherapy is now being used throughout Europe for treatment of patients with ovarian cancer who have previously failed a platinum-containing chemotherapy regimen, and in many countries to treat metastatic breast cancer. Nurses need to be equipped to care for these patients receiving Paclitaxel. This paper introduces nurses to Paclitaxel, the history of its development, its mechanism of action, potential side-effects and administration. Paclitaxel's side-effects include hypersensitivity reactions, neutropaenia, peripheral neuropathy, asymptomatic bradycardia, alopecia, malaise, myalgias and arthralgias. Administration guidelines will be discussed because Paclitaxel leaches plasticizer from polyvinyl chloride (PVC) intravenous-giving sets normally used to administer chemotherapy, hence an alternative delivery system is required.

U2 - 10.1111/j.1365-2354.1996.tb00226.x

DO - 10.1111/j.1365-2354.1996.tb00226.x

M3 - Journal article

VL - 5

SP - 147

EP - 152

JO - European Journal of Cancer Care

JF - European Journal of Cancer Care

SN - 1365-2354

IS - 3

ER -